Abstract
Purpose: To evaluate the impact of the COVID-19 national emergency declaration on contraceptive dispensing trends among commercially insured Kentucky females. Methods: Data ranging from 1/7/2019 through 12/27/2020 for female enrollees aged 19–44 with a primary residence in Kentucky were extracted from the Merative Marketscan Commercial Claims and Encounters Database. A segmented regression analysis was used for statistical modeling of an interrupted time series design to describe changes in weekly contraceptive (oral, transdermal, and vaginal) dispensing rates and days' supply following the COVID-19 national emergency. Results: A total of 90 541 enrollees met study inclusion criteria. The estimated weekly contraceptive dispensing rate per 100 reproductive-aged female enrollees was 3.22 (95% confidence interval [CI] 3.16–3.28) at the beginning of the pre-pandemic period. Following the national emergency, an immediate estimated rate increase of 0.11 (95% CI 0.01–0.21; p = 0.030) was seen with no change in trend. At the beginning of the pre-pandemic period, the estimated weekly percentage of days' supply > 28 days was 29.2% (95% CI 28.8–29.6) with an increasing trend of 1.1% every 10 weeks (slope 0.11 [95% CI 0.09–0.12; p < 0.001]). Following the national emergency, an immediate decrease of 1.5% (95% CI −2.2 to −0.8; p < 0.001) was observed, followed by sustainment of the pre-pandemic trend. No differential impacts were seen with regard to age group (19–26 vs. 27–44) or rural–urban classification. Conclusions: Following the COVID-19 national emergency declaration, trends in both contraceptive dispensing and days' supply among commercially insured Kentucky females were relatively stable, suggesting multiple behavioral and policy-related factors potentially overshadowing changes in access.
Original language | English |
---|---|
Article number | e70159 |
Journal | Pharmacoepidemiology and Drug Safety |
Volume | 34 |
Issue number | 5 |
DOIs | |
State | Published - May 2025 |
Bibliographical note
Publisher Copyright:© 2025 John Wiley & Sons Ltd.
Funding
Funding: This work was supported by National Institutes of Health (The US NIH) (UL1TR001998). The project was supported, in part, by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences through grant number UL1TR001998. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funder had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. This work was supported by National Institutes of Health (The US NIH) (UL1TR001998). Funding: The project was supported, in part, by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences through grant number UL1TR001998. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funder had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.
Funders | Funder number |
---|---|
National Center for Advancing Translational Sciences | |
National Institutes of Health | UL1TR001998 |
National Institutes of Health | |
National Center for Advancing Translational Sciences | UL1TR001998 |
Keywords
- contraceptive behavior
- family planning
- health services accessibility
- hormonal contraception
- interrupted time series analysis
- pharmacy
ASJC Scopus subject areas
- Epidemiology
- Pharmacology (medical)